Contact us
Please fill out the details below and we will get back to you shortly.
Thank you!
We will be contacting you soon..
Close
We will be contacting you soon..
Oops! Something went wrong while submitting the form.
December 2019 - Jay Sparks, host of Finding Unique Value podcast, chats with Dr. Anquetil about how he has leveraged his unique science and business background to create value and solve an unmet need with potential to help millions of people.
If you’re squeamish about needles, you’ll be delighted to know that Portal Instruments is developing technology that will allow needle-free injections of important medications through the skin. It’s especially important for people with chronic conditions that require constant injections.
Portal’s CEO and co-founder, Dr. Patrick Anquetil is DOING THIS. He’s a scientist and engineer who is also able to see the world through the lens of business, allowing him to spot opportunity in a very important industry.
It’s a great example of how business – and even profit – can drive the development of technology with the potential to help millions of people.
Jay Sparks, host of Finding Unique Value podcast, chats with Dr. Anquetil about how he has leveraged his unique science and business background to create value and solve an unmet need with potential to help millions of people.
The podcast discusses Dr. Anquetil’s journey so far, and much more, including…
– How to protect breakthrough inventions with the government’s help
– The hardest part of running a startup and how to overcome it
– Fundraising tips for getting the capital you need
– Why Dr. Anquetil’s education takes a backseat, even in this highly specialized industry
– And more
June 30, 2022 - Logan Merrill has taken testosterone injections for 6 years. In this piece, Logan talks about his transition and the process of taking his injections. This blog was written by Logan Merrill for Portal Instruments. All opinions and experiences shared are entirely his own.
May 10, 2022 - Portal Instruments has been featured in Fierce Pharma. "Gerresheimer invests in Portal's needle-free drug delivery, teeing Takeda partner up to advance tech", showcases Gerresheimer's agreement with Portal to support the development of the needle-free drug delivery platform.
Today Portal Instruments announced a joint publication with Regeneron on the PRIME needle-free injection platform. The findings provided crucial data on Portal's platform, demonstrating the ability to deliver high-viscosity biologics with volume flexibility and tailored injection depths.
Please fill out the details below and we will get back to you shortly.